



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Nephrology

**Manuscript NO:** 62391

**Title:** Nephrogenic Systemic Fibrosis : a frivolous entity

**Reviewer's code:** 00503254

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** India

**Manuscript submission date:** 2021-01-09

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-01-28 08:20

**Reviewer performed review:** 2021-02-10 04:58

**Review time:** 12 Days and 20 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

In this manuscript, the authors review the clinical features, pathogenesis, histology, risk factors, and treatment of nephrogenic systemic fibrosis. This paper concludes that gadolinium-based contrast agents should be used with care when performing magnetic resonance imaging in patients with kidney dysfunction. This paper is both clinically interesting and helpful; however, it requires considerable revision by the authors. Minor comments: 1. Reference number 19 is placed after the number 2. Please review and correct the numbering of the references. 2. The authors should show the insertion point of Table 2 in the text.